AMR Action Fund Portfolio Company UTILITY Therapeutics Granted FDA Approval for Pivmecillinam

The AMR Action Fund announced today that one of its portfolio companies, UTILITY Therapeutics, Ltd., received approval from the U.S. Food and Drug Administration (FDA) for the antibiotic PIVYA™ (pivmecillinam) for the treatment of uncomplicated UTIs (uUTI). The FDA previously designated pivmecillinam as a qualified infectious disease product (QIDP), a designation reserved for certain antibacterial and antifungal drugs that treat serious or life-threatening infections.

UTIs are one of the most common infections worldwide, disproportionately affecting women and the elderly. There were more than 400 million UTIs globally in 2019, a 60 percent increase since 1990, according to a recent study in Frontiers in Public Health. In the U.S. specifically, UTIs afflict millions of women each year, costing the health system an estimated $2.14 billion annually, according to findings published in Clinical Infectious Diseases.

“Urinary tract infections caused by gram-negative bacteria are a substantial and growing burden, and the efficacy of available first-line therapies is waning in the face of mounting antimicrobial resistance. Bringing pivmecillinam to the U.S. has the potential to benefit patients suffering from these harmful infections by giving clinicians a new, urgently needed treatment option for uncomplicated UTIs,” AMR Action Fund CEO Henry Skinner, PhD, said. “FDA approval also has the potential to support efforts to provide access to this important antibiotic in low- and middle-income countries where it has not yet been approved and where the burden of bacterial infections is enormous and fewer effective therapies are available.”

Pivmecillinam is the first antibiotic in approximately 20 years to be approved by the FDA for uUTI. Pivmecillinam is an oral prodrug of mecillinam that has a unique mechanism of action against gram-negative bacteria and is currently marketed in some European countries. Numerous studies have demonstrated its efficacy and safety profile, and it has maintained a low resistance profile after years of use in Nordic markets.

“Approximately 50 percent of women in the U.S. will suffer from a UTI during their lifetime and treatment options for these often-debilitating infections have lagged,” Beth Battaglino, RN-C, CEO of Healthy Women said. “As rates of antimicrobial resistance continue to rise, we must ensure that healthcare providers have the necessary tools to meet the needs of their patients.”

Michael Hodin, PhD, CEO of the Global Coalition on Aging, added, “Urinary tract infections are a scourge among older adults that are responsible for approximately 25 percent of all geriatric hospitalizations in the U.S. We applaud UTILITY Therapeutics for recognizing where the patient need is, and we commend the AMR Action Fund for supporting UTILITY’s efforts to bring pivmecillinam to patients in the U.S.”

Pivmecillinam marks the first antibiotic drug of an AMR Action Fund portfolio company to earn regulatory approval.


About the AMR Action Fund

The AMR Action Fund is a mission-driven venture capital fund investing in antibiotics, antifungals, and other antimicrobial technologies. The Fund plans to invest approximately US$1 billion into clinical-stage biotech companies to help bring two to four new antibiotics to market by 2030.

Source: AMR Action Fund

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Global Coalition on Aging, Leading G7 Government Officials, Call for Incentivized Antibiotic Innovation

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.

New Report From the Global Coalition on Aging Highlights the Connection Between Adult Immunization and Economic Health in Aging APEC Region

As leaders from across the Asia-Pacific Economic Cooperation (APEC) region convene in San Francisco over the next week, a new report from the Global Coalition on Aging (GCOA) points to investments in healthy aging as a growing economic imperative amid the region’s changing demographics. According to the new report, programs that keep populations healthy, active, and productive – like adult immunization – are increasingly becoming a prerequisite for economic stability and growth.

Menopause, the Silver Economy and Workplace Opportunities

As we recognise World Menopause Day, take a moment to consider the economic power, diverse expertise and skills, and incredible societal contributions of the estimated 1.1 billion post-menopausal women worldwide by 2025—a population on-par with China or India, and dwarfing any other country. Indeed, if we want to fuel the vibrant $15 trillion silver economy, societies, governments, and employers must empower older women in the future of work, including solutions that fight stigma and increase workplace support related to menopause.